Serum markers of hepatic fibrogenesis in cystic fibrosis liver disease

Pereira, Tamara N.; Lewindon, Peter; Smith, Jeffery L.; Murphy, Tamara C.; Lincoln, Doug; Shepherd, Ross W.; Ramm, Grant A.

doi:10.1016/j.jhep.2004.06.032

Cited by 57 publications

(59 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum C-IV has been used to diagnose liver fibrosis in diseases that evolved with sinusoid capilarisation (Hiramatsu et al 1995, Murawaki et al 2001, pereira et al 2004, Santos et al 2005, Halfon et al 2006, Yoneda et al 2007). Comparing serum C-IV levels between groups, according to the clinical classification of patients with mansonic and hematobic schistosomiasis, Shahin et al (1992) found high serum levels in patients with hepatosplenic schistosomiasis.…”

Section: Discussionmentioning

confidence: 99%

Serum hyaluronan and collagen IV as non-invasive markers of liver fibrosis in patients from an endemic area for schistosomiasis mansoni: a field-based study in Brazil

Marinho¹,

Bretas

Voieta³

et al. 2010

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Serum hyaluronan and collagen IV as non-invasive markers of liver fibrosis in patients from an endemic area for schistosomiasis mansoni: a field-based study in Brazil

Marinho¹,

Bretas

Voieta³

et al. 2010

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

show abstract

“…This study is part of a long-term prospective cohort study of patients with CFLD identified and referred from the CF Clinic, Royal Children's Hospital, Brisbane, previously well documented 19,21,[26][27][28] . CFLD was defined as two of the following: (i) hepatomegaly ± splenomegaly; (ii) persistent (>6mo) elevation of serum alanine aminotransferase (>1.5x upper limit normal); and (iii) abnormal liver ultrasound (abnormal echogenicity or nodular edge).…”

Section: Methodsmentioning

confidence: 99%

Taurocholate Induces Biliary Differentiation of Liver Progenitor Cells Causing Hepatic Stellate Cell Chemotaxis in the Ductular Reaction

Pozniak

Pearen

Pereira

et al. 2017

The American Journal of Pathology

Self Cite

View full text Add to dashboard Cite

“…Two studies linked elevated plasma TIMP-1 and TIMP-2 levels to the presence of liver disease in CF patients. 55,56 Thus, plasma levels of MMP-8, MMP-9, and TIMPs may have utility as prognostic biomarkers for CF.…”

Section: Mmp Levels In Cf Blood Samplesmentioning

confidence: 99%

Matrix metalloproteinases in cystic fibrosis: pathophysiologic and therapeutic perspectives

Owen

Jojas-Quintero²

2016

MNM

View full text Add to dashboard Cite

Cystic fibrosis (CF) is the most common inherited disease in the Caucasian population. CF is caused by loss-of-function mutations in the CFTR gene leading to an altered electrolyte and water movement into the airway surface liquid, dehydration of the mucus layer, defective mucociliary clearance, and increased susceptibility to airway bacterial infections. CF is characterized by airway neutrophilic inflammation and activation of airway epithelial cells leading to increased airway levels of various matrix metalloproteinases (MMPs). Herein, we review MMP structure, regulation, and activity, along with the literature on MMPs expression in CF and the contributions of MMPs to CF pathogenesis. Numerous studies report elevated levels of MMPs (especially MMP-8, MMP-7, and MMP-9) in blood and/or lung samples from CF patients and have correlated MMP levels with measures of lung inflammation and injury and/or clinical parameters. No study has yet investigated the contributions of MMPs to the pathogenesis of CF using MMP gene-targeted murine of CF. Based upon the known activities of MMPs in animal models of other lung diseases, we hypothesize that some MMPs (such as MMP-8 and MMP-9) may amplify airway inflammation, and promote airway injury and airway-remodeling processes, or inhibit chloride epithelial transport by inhibiting activation of the CFTR (MMP-2). Other MMPs (such as MMP-7 and MMP-12) may limit the severity of CF by activating host defense proteins to enhance pathogen clearance from the airways, directly killing pathogens that colonize the airways of CF patients and/or promoting epithelial repair. We discuss potential approaches to selectively target MMPs to develop novel therapies that limit the high morbidity and mortality associated with CF.

show abstract

Serum markers of hepatic fibrogenesis in cystic fibrosis liver disease

Cited by 57 publications

References 30 publications

Serum hyaluronan and collagen IV as non-invasive markers of liver fibrosis in patients from an endemic area for schistosomiasis mansoni: a field-based study in Brazil

Serum hyaluronan and collagen IV as non-invasive markers of liver fibrosis in patients from an endemic area for schistosomiasis mansoni: a field-based study in Brazil

Taurocholate Induces Biliary Differentiation of Liver Progenitor Cells Causing Hepatic Stellate Cell Chemotaxis in the Ductular Reaction

Matrix metalloproteinases in cystic fibrosis: pathophysiologic and therapeutic perspectives

Contact Info

Product

Resources

About